Evidence map›Paper›PMID 30513107›Full record

ArticlePloS one2018

Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.

Regina Juanbeltz, Alejandra Pérez-García, Aitziber Aguinaga, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Silvia Goñi-Esarte, Jesús Repáraz, José Manuel Zozaya, Ramón San Miguel and 3 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05146609 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population

TypeinterventionalSponsorUniversity of La LagunaRan2022 to 2024Enrolled1,384ConditionsHepatitis CArmsScreening HCV. HR-HOSPITAL, Screening HCV. HR-DDP, Screening HCV. GP-HOSPITAL, Screening HCV. GP-PCC
NCT05756738 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Acceptance and Feasibility of Hepatitis c Screening Strategies in Social Insertion Centers With Alternative Sentences to Prison and Open System

TypeinterventionalSponsorUniversity of La LagunaRan2023 to 2024Enrolled854ConditionsHepatitis C VirusArmsDried blood spot testing
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Data Resource Profile: Results Analysis Base of Navarre (BARDENA).International journal of epidemiology · 2023
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population.Liver international : official journal of the International Association for the Study of the Liver · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Regina JuanbeltzInstituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
Alejandra Pérez-GarcíaCIBER Epidemiología y Salud Pública, Pamplona, Spain.
Aitziber AguinagaDepartment of Clinical Microbiology, Complejo Hospitalario de Navarra-IdiSNA, Pamplona, Spain.
Iván Martínez-BazInstituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
Itziar CasadoInstituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.
Cristina BurguiCIBER Epidemiología y Salud Pública, Pamplona, Spain.
Silvia Goñi-EsarteDepartment of Gastroenterology and Hepatology, Complejo Hospitalario de Navarra, Pamplona, Spain.
Jesús RepárazDepartment of Internal Medicine, Complejo Hospitalario de Navarra-IdiSNA, Pamplona, Spain.
José Manuel ZozayaDepartment of Gastroenterology and Hepatology, Complejo Hospitalario de Navarra, Pamplona, Spain.
Ramón San MiguelDepartment of Pharmacy, Complejo Hospitalario de Navarra-IdiSNA, Pamplona, Spain.
Carmen EzpeletaDepartment of Clinical Microbiology, Complejo Hospitalario de Navarra-IdiSNA, Pamplona, Spain.
Jesús CastillaInstituto de Salud Pública de Navarra-IdiSNA, Pamplona, Spain.ORCID 0000-0002-6396-7265
EIPT-VHC Study Group
Complejo Hospitalario de Navarra · ESInstituto de Salud Pública de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress and difficulties in the elimination of HCV infection in Navarra, Spain.

methodsUsing electronic healthcare databases, we performed a population-based prospective cohort study to describe changes in the prevalence of diagnosed active HCV infection at the beginning of 2015 and the end of 2017, the rate of new diagnoses and the rate of post-treatment viral clearance (PTVC) during this period.

resultsAt the beginning of 2015 there were 1503 patients diagnosed with positive HCV-RNA, 2.4 per 1000 inhabitants, and at the end of 2017 the prevalence had decreased by 47%. In the study period, 333 (18 per 100,000 person-years) new positive HCV-RNA cases were detected, but only 76 (23%; 4.2 per 100,000 person-years) did not have anti-HCV antibodies previously detected. Prevalent cases and new diagnoses of active infection were more frequent in men, people born in 1950-1979, HIV-infected patients and in those with lower income levels. Among patients with HCV-RNA, 984 achieved PTVC (22.7 per 100 person-years). PTVC was less frequent in patients born before 1940, in immigrants and in patients with lower income levels.

conclusionsThe prevalence of diagnosed active HCV infection has dropped by almost half over three years, because the number of patients with PTVC was much higher than the number of new diagnoses. Interventions specifically targeted at population groups with less favourable trends may be necessary.

Indexed as

AdolescentAdultAgedAged, 80 and overAntiviral AgentsCohort StudiesDatabases, FactualFemaleHepacivirusHepatitis CHepatitis C AntibodiesHumansMaleMiddle AgedOdds RatioPrevalenceAntiviral AgentsHepatitis C AntibodiesRNA, Viral

Identifiers

PMID30513107
PMCPMC6279228
OpenAlexW2903414073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.